The recent reshuffle in the GLP-1 market has renewed attention on large, currently out-of-favor drugmakers. In late 2025, Novo Nordisk’s GLP-1 pill approval and Eli Lilly’s competitive injectables reshaped investor expectations, while legacy firms Bristol Myers Squibb, Merck and Pfizer trade well below prior highs. Each of the three names offers differing yields, payout ratios and patent timelines that matter for income and total-return investors. This article assesses their valuations, near-term risks and why they may appeal to contrarian buyers.
Key Takeaways
- Bristol Myers Squibb yields about 4.6% with a payout ratio near 85%; the stock is roughly 30% below its peak and faces patent losses for Revlimid and Pomalyst in the coming years.
- Merck yields about 3.2% with a payout ratio near 45%; its flagship oncology drug Keytruda remains protected in major markets until 2028 and in some territories into the early 2030s.
- Pfizer offers a roughly 6.8% yield but currently shows a payout ratio above 100%, indicating dividend risk; the share price is over 50% below its high-water mark.
- Novo Nordisk’s recent approval of an oral GLP-1 and an expected early-2026 launch accelerated sector competition and pushed incumbents to adjust pipelines and partnerships.
- Large-cap pharmas typically manage patent cliffs through M&A, licensing and new indications; that playbook underpins the argument for buying established companies on weakness.
Background
The introduction of GLP-1 medicines for weight loss and metabolic disease has been one of the pharmaceutical sector’s defining stories in 2024–2025. Novo Nordisk initially led the category with injectable therapies; Eli Lilly followed with highly competitive injections that captured market share. In late 2025, regulatory approval for an oral GLP-1 from Novo Nordisk intensified competition and prompted sharp market moves across the industry.
Large drugmakers’ valuations swing with pipeline news, patent expirations and the timing of new launches. Known as the patent-cliff dynamic, this pattern repeatedly reshapes revenue forecasts: blockbuster losses can depress earnings, while successful launches or acquisitions can restore growth. Investors often reassess defensive income plays and turnaround candidates during these cycles.
Main Event
The most recent trigger was Novo Nordisk’s green light for an oral GLP-1 product, which the company expects to bring to market in early 2026. The approval shifted investor expectations toward easier-to-administer therapies and led to renewed share-price volatility across the sector. Novo’s stock jumped on the announcement, reflecting optimism about market reordering, but the company remains more than 50% below its all-time high.
Pfizer’s own GLP-1 candidate failed to meet expectations, and the company faces a material patent cliff on at least one key product. Management has responded by buying assets and partnering with firms in China to broaden distribution for promising candidates, but the near-term income profile is stressed: the dividend yield sits near 6.8% while reported payout coverage is above 100% today.
Bristol Myers Squibb has been actively acquiring and diversifying to blunt upcoming revenue losses from drugs such as Revlimid and Pomalyst. The firm’s share price has fallen about 30% from its peak, but its 4.6% yield and an 85% payout ratio give it some—but limited—room to maintain distributions through revenue transitions.
Merck is positioned as the most conservative of the three for income-seeking investors. Keytruda remains a large revenue driver with patent protection in the U.S. until 2028 and additional international protections into the early 2030s. With a payout ratio around 45% and a yield near 3.2%, Merck appears better insulated against dividend stress while it advances pipeline candidates and delivery strategies that might extend economic life.
Analysis & Implications
Buying large pharmaceutical firms on sector-wide pessimism is a classic contrarian approach. The argument rests on two assumptions: that established companies can replenish lost revenue through M&A, new indications, or next-generation formulations; and that current market prices already reflect much of the downside risk. For investors focused on total return over multiple years, acquiring shares at depressed valuations can offer asymmetric upside if at least one remediation path succeeds.
Dividend investors must weigh yield against payout sustainability. Pfizer’s headline yield is attractive, but a payout ratio above 100% signals that distributions are running ahead of earnings and may be supported by asset sales or balance-sheet flexibility—neither of which is as durable as operating cash flow. In contrast, Merck’s mid-single-digit yield plus a lower payout ratio offers a steadier income profile.
Patent expirations remain the dominant near-term earnings risk. Bristol Myers faces imminent losses on high-revenue oncology drugs that will pressure near-term margins. The company’s series of acquisitions aims to diversify that exposure but introduces execution risk—integrations can take years to deliver promised synergies. Successful integration or a hit from the pipeline would materially change valuation casework.
On the other hand, sector-wide innovation—such as oral GLP-1s or combination therapies—creates upside for any firm that secures a meaningful position. Partnerships, licensing deals and targeted acquisitions can rapidly alter competitive dynamics; investors should monitor deal flow and late-stage trial readouts as immediate catalysts.
Comparison & Data
| Company | Current Price | Dividend Yield | Payout Ratio | Decline from High | Key Patent / Note |
|---|---|---|---|---|---|
| Pfizer | $25.09 | ~6.8% | >100% | >50% | GLP-1 candidate setback; approaching patent expirations |
| Bristol Myers Squibb | $54.64 | ~4.6% | ~85% | ~30% | Revlimid/Pomalyst patent cliff; active M&A |
| Merck | $106.78 | ~3.2% | ~45% | ~20% | Keytruda patents to 2028; international protection into early 2030s |
The table above condenses valuation and income metrics central to investors’ decision-making. These snapshots do not substitute for full financial analysis, but they highlight how payout coverage, yield and patent timelines differ among the three names and inform risk tolerance.
Reactions & Quotes
Large-cap drugmakers have historically managed patent losses through targeted acquisitions and new-indication launches, a pattern we expect to continue.
Industry analyst
The quote above summarizes why many investors remain comfortable holding major pharmas through cycles: there is a well-worn toolkit for replacing lost revenue, though timing and execution vary.
We are pursuing strategic partnerships and selective acquisitions to shore up our late-stage pipeline and geographic reach.
Company statement
Several firms have issued similar statements emphasizing portfolio reshaping and alliance-building as their primary response to GLP-1 competition and patent expiry timelines.
Dividend investors should focus on payout coverage, not headline yield alone; high yields with weak coverage carry real distribution risk.
Portfolio manager
This practical reminder frames why Merck’s lower payout ratio looks more attractive to income-conservative investors compared with Pfizer’s higher but less-covered dividend.
Unconfirmed
- Long-term market share effects of Novo Nordisk’s oral GLP-1 remain uncertain until post-launch real-world uptake data are available.
- The precise timing and commercial impact of future generic or biosimilar entries for each patent at risk are subject to regulatory outcomes and settlement agreements.
- Projections about dividend changes at Pfizer, Bristol Myers Squibb or Merck depend on quarterly results and management decisions that have not been finalized.
Bottom Line
Bristol Myers Squibb, Merck and Pfizer each present a different combination of income, risk and turnaround potential. Merck offers the most conservative income profile today thanks to lower payout coverage and extended protection for Keytruda. Bristol Myers trades at a discount that reflects near-term oncology patent losses but may reward successful M&A and pipeline progress. Pfizer’s high yield appears attractive but comes with meaningful near-term payout risk while the company resets its pipeline.
For long-term investors, these names merit consideration as part of a diversified pharma allocation, with position size calibrated to one’s tolerance for patent-cliff execution risk and dividend sustainability. Monitoring clinical readouts, deal announcements and quarterly cash-flow trends will be critical to updating the investment case over the next 12–36 months.